ADARx Pharmaceuticals Prices Upsized $446.3M IPO at $17 per Share
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-25. Check what remains unresolved below before relying on it.
What does this change in the investment case for ADARx Pharmaceuticals?
Direct equity issuance injects $446.3M gross cash onto ADRX balance sheet to fund clinical-stage siRNA pipelines.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factADARx Pharmaceuticals, a clinical biotechnology developer of siRNA therapeutics, priced its IPO at $17.00 per share. |
| What else was confirmed? | Reported factThe offering was upsized to 26.25 million shares, raising approximately $446.3 million in gross proceeds. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for ADRX yet — this is the next research task. |
| What would change the assessment? | UnknownADRX opening trade print and first-day volume — Monitor initial Nasdaq execution pricing relative to the $17.00 issue level. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · ADARx Pharmaceuticals, a clinical biotechnology developer of siRNA therapeutics, priced its IPO at $17.00 per share.
- · The offering was upsized to 26.25 million shares, raising approximately $446.3 million in gross proceeds.
- · Trading commences on the Nasdaq under the ticker 'ADRX' on September 25, 2026.
Public research record
Research framework · page evidenceCompleted event assessment
primary equity issuance establishing initial trading valuation
| Type | Claim | Scope |
|---|---|---|
| Assumption | ADARx Pharmaceuticals, a clinical biotechnology developer of siRNA therapeutics, priced its IPO at $17.00 per share. | 2026-09-25 |
| Interpretation | primary equity issuance establishing initial trading valuation | ADRX |
Countercase, invalidators, and sources
Debut trades at a solid premium to the $17 offer price, reinforcing institutional appetite for clinical biotech equity issues.
- · ADRX opening trade print and first-day volume — Monitor initial Nasdaq execution pricing relative to the $17.00 issue level.
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering · 2026-09-24
What remains unresolved
- Base path
- ADRX trades in line with the $17 pricing level in initial secondary market turnover.
- Adverse path
- Secondary market weakness breaks below the issue price amid broader risk aversion.
- Supportive path
- Debut trades at a solid premium to the $17 offer price, reinforcing institutional appetite for clinical biotech equity issues.
- · ADRX opening trade print and first-day volume — Monitor initial Nasdaq execution pricing relative to the $17.00 issue level.today
Evidence
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering2026-09-24
“ADARx Pharmaceuticals... priced its IPO at $17 per share for 26.25 million shares, generating approximately $446.3 million in gross proceeds. The company will begin trading on Nasdaq under ticker 'ADRX' on September 25, 2026.”
Supports: ADARx priced upsized $446.3M IPO at $17 per share to trade on Nasdaq as ADRX.